Navigation Links
A longer lasting tumor blocker
Date:4/28/2009

On the heels of dismaying reports that a promising antitumor drug could, in theory, shorten patients' long-term survival, comes a promising study by a Japanese team of researchers that suggests a potentially better option. The study appears in the May 11 issue of the Journal of Experimental Medicine (online April 27).

Many cancer treatments work by disrupting the formation of new blood vessels that feed growing tumors. Agents that block a vessel-promoting factor called VEGF have shown promise in human clinical trials. But recent studies in mice show that when treatment stops, tumor growth rapidly resumes. Now, Yoshiaki Kubota and colleagues find that blocking a different molecule, called M-CSF, suppressed tumor growth even after treatment was stopped.

Kubota and his team compared the efficacy of inhibitors against M-CSF and VEGF in mice with a certain kind of bone tumor. Three weeks of anti-VEGF treatment suppressed tumor growth but, similar to other recent reports, the tumors bounced back when the drug treatment was curtailed. Tumor growth in mice on a similar regiment of an M-CSF inhibitor remained suppressed in the absence of drug.

Another distinction between the two inhibitors was the type of vessel growth that was blocked. Blocking VEGF prevented dangerous vessels from growing such as those that feed tumors. But it also stopped beneficial vessels from growing, such as those that help injured tissues heal. Blocking M-CSF, on the other hand, only impeded bad vessel growth.

Most likely, the antiM-CSF treatment had a lasting effect because it resulted in damage to the scaffolding that surrounds cancerous vessels, robbing the tumors of the structural support they need to grow. Meanwhile, the scaffold of mice treated with anti-VEGF remained intact.

M-CSF levels soar in patients with osteosarcoma (a malignant bone cancer), breast cancer and prostate cancer, making these cancers potentially the most responsive
'/>"/>

Contact: Amy Maxmen
amaxmen@rockefeller.edu
Rockefeller University Press
Source:Eurekalert

Page: 1 2

Related biology news :

1. Turtles no longer turned into souvenirs
2. Inactivity of proteins behind longer shelf life when freezing
3. No longer a gray area: Our hair bleaches itself as we grow older
4. Shorter wait means longer life for kidney transplant candidates
5. Living longer thanks to the longevity gene
6. For fats, longer may not be better
7. Deprived of a sense of smell, worms live longer
8. Formula discovered for longer plant life
9. The mystery of mass extinctions is no longer murky
10. Mouse study: When it comes to living longer, its better to go hungry than go running
11. Antioxidant users dont live longer, analysis of studies concludes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... mutated or expressed in high concentrations can cause normal cells ... demonstrating that Ras, one of the first oncogenes discovered, has ... Ph.D. student Oded Rechavi and his fellow researchers at Tel ... the ability to transfer from cancer cells into immune cells ...
... CORVALLIS, Ore. Researchers at Oregon State University recently completed ... toxicology, and the findings challenge some basic concepts about how ... considered safe. The study found that acceptable levels of ... higher than is currently believed. It also indicates that for ...
... University have developed a laboratory robot that can successfully locate ... to its exact location - all without the need for ... to believe that in the future, such a robot could ... might also be used for such medical procedures as placing ...
Cached Biology News:Cancer-causing protein can also help fight the tumors it causes 2Improved method developed to test carcinogen risk 2Improved method developed to test carcinogen risk 3Autonomous robot detects shrapnel 2Autonomous robot detects shrapnel 3
(Date:5/4/2015)... 4, 2015  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... address unmet medical needs in the areas of inflammation, ... presenting preclinical data from three of its biodefense programs ... Technology Conference on May 12-14, 2015 to be held ... Plaza, St. Louis MO 63101. ...
(Date:5/4/2015)... , May 4, 2015   Sentrian ™, the ... has teamed with the Scripps Translational Science Institute ... on 1,000 patients with chronic obstructive pulmonary disease (COPD), ... and is the nation,s third leading cause of death. ... CareMore Health System , a wholly owned subsidiary of ...
(Date:5/1/2015)... May 1, 2015 Pfenex Inc. (NYSE ... the development of biosimilar therapeutics including high value ... its first quarter 2015 financial results will be ... open of market. At 8:30 am Eastern Time, Pfenex ... the financial results and provide a business update. A ...
(Date:5/1/2015)... -- According to a new market ... by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), by ... Analysis & Global Forecast to 2019", published by ... Market for the forecast period of 2014 to ... Billion by 2019 from $1.425 Billion in 2014, ...
Breaking Biology Technology:Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4
... 13 ,Exelixis, Inc. (Nasdaq: EXEL ) today announced ... common stock. The net proceeds of the,offering are approximately ... shares in the offering are being sold by,Exelixis. Exelixis ... up to an additional 1,050,000 shares of common stock. ...
... PITTSBURGH, Sept. 13 The Pittsburgh Life ... region,s life,sciences industry on a fast track ... and Chief Executive Officer, Renal Solutions, Inc., ... Initiatives, UPMC, John,L. Miclot, President and Chief ...
... September 13 In order,to meet its obligations under ... ("Shire") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) is,publishing today ... June 2007,in accordance with International Financial Reporting Standards (IFRS). ... 2007, Shire announced its results in,respect of the same ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors 2The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors 3IFRS Information - First Half of 2007 2IFRS Information - First Half of 2007 3IFRS Information - First Half of 2007 4IFRS Information - First Half of 2007 5IFRS Information - First Half of 2007 6IFRS Information - First Half of 2007 7IFRS Information - First Half of 2007 8IFRS Information - First Half of 2007 9IFRS Information - First Half of 2007 10IFRS Information - First Half of 2007 11IFRS Information - First Half of 2007 12IFRS Information - First Half of 2007 13IFRS Information - First Half of 2007 14IFRS Information - First Half of 2007 15IFRS Information - First Half of 2007 16IFRS Information - First Half of 2007 17IFRS Information - First Half of 2007 18IFRS Information - First Half of 2007 19IFRS Information - First Half of 2007 20IFRS Information - First Half of 2007 21IFRS Information - First Half of 2007 22IFRS Information - First Half of 2007 23IFRS Information - First Half of 2007 24IFRS Information - First Half of 2007 25IFRS Information - First Half of 2007 26IFRS Information - First Half of 2007 27IFRS Information - First Half of 2007 28IFRS Information - First Half of 2007 29IFRS Information - First Half of 2007 30IFRS Information - First Half of 2007 31IFRS Information - First Half of 2007 32IFRS Information - First Half of 2007 33
...
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... for 10 separate biopanning experiments, complexity ... gIII Sequencing Primer (100 pmol), for ... Primer (100 pmol), for automated DNA ... Control target (Streptavidin) and Elutant (Biotin), ...
Biology Products: